This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (18)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Evidence-Based Medicine  • Review  • Diabetes Mellitus  • Alert me on articles by topic

Johannes Plank, MD; Andrea Siebenhofer, MD; Andrea Berghold, MsC, PhD; Klaus Jeitler, MD; Karl Horvath, MD; Peter Mrak, MD; Thomas R. Pieber, MD

Arch Intern Med. 2005;165:1337-1344.

Background  This article compares the effect of treatment with short-acting insulin (SAI) analogues vs regular insulin on glycemic control, hypoglycemic episodes, quality of life, and diabetes-specific complications.

Methods  Electronic searches (Cochrane Library, MEDLINE, and EMBASE) and additional searching (pharmaceutical companies, experts, approval agencies, abstracts of diabetology meetings) were performed. Two reviewers independently screened randomized controlled trials to determine inclusion.

Results  Forty-two randomized controlled trials that assessed the effect of SAI analogues vs regular insulin in 7933 patients with type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes mellitus were identified. The weighted mean difference between hemoglobin A_1c values obtained using SAI analogues and regular insulin was –0.12% (95% confidence interval [CI], –0.17% to –0.07%) for adult patients with type 1 diabetes mellitus and –0.02% (95% CI, –0.10% to 0.07%) for patients with type 2 diabetes mellitus. The standardized mean difference for overall hypoglycemia (episodes per patient per month) was –0.05 (95% CI, –0.22 to 0.11) and –0.04 (95% CI, –0.12 to 0.04) comparing SAI analogues with regular insulin in adult patients with type 1 and type 2 diabetes mellitus, respectively. No differences between treatments were observed in children with type 1 diabetes, pregnant women with type 1 diabetes mellitus, and women with gestational diabetes. Concerning quality of life, improvement was observed only in open-label studies in patients with type 1 diabetes mellitus. No differences were seen in a double-blinded study of patients with type 1 or in the studies of patients with type 2 diabetes mellitus.

Conclusion  Our analysis suggests only a minor benefit to hemoglobin A_1c values in adult patients with type 1 diabetes mellitus but no benefit in the remaining population with type 2 or gestational diabetes from SAI analogue treatment.

Author Affiliations: Department of Internal Medicine, Division of Diabetes and Metabolism (Drs Plank, Siebenhofer, Jeitler, Horvath, and Pieber), and Institute for Medical Informatics, Statistics and Documentation (Dr Berghold), Medical University, Graz, Department of Internal Medicine, Landeskrankenhaus, Hörgas (Dr Mrak), and Joanneum Research, Institute of Medical Technologies and Health Management, Graz (Drs Jeitler and Pieber), Austria.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Unexplained Hyperglycemia in Continuous Subcutaneous Insulin Infusion: Evaluation and Treatment
Ponder et al.
The Diabetes Educator 2008;34:327-333.
ABSTRACT | FULL TEXT  

Continuing Stability of Center Differences in Pediatric Diabetes Care: Do Advances in Diabetes Treatment Improve Outcome?: The Hvidoere Study Group on Childhood Diabetes
de Beaufort et al.
Diabetes Care 2007;30:2245-2250.
ABSTRACT | FULL TEXT  

Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine.
Erickson et al.
Am J Health Syst Pharm 2006;63:1862-1871.
ABSTRACT | FULL TEXT  

Use of new insulins in children
Regan and Dunger
EDUCATION AND PRACTICE 2006;91:ep47-ep53.
FULL TEXT